Literature DB >> 34403752

Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors.

Tong Ye1, Feng Li1, Guanghui Ma1, Wei Wei2.   

Abstract

In recent years, personalized cancer vaccines have gained increasing attention as emerging immunotherapies with the capability to overcome interindividual differences and show great benefits for individual patients in the clinic due to the highly tailored vaccine formulations. A large number of materials have been studied as delivery vectors to enhance the therapeutic performance of personalized cancer vaccines, including artificial materials, engineered microorganisms, cells and cell derivatives. These delivery vectors with distinct features are employed to change antigen biodistributions and to facilitate antigen uptake, processing and presentation, improving the strength, velocity, and duration of the immune response when delivered by different strategies. Here, we provide an overview of personalized cancer vaccine delivery vectors, describing their materials, physicochemical properties, delivery strategies and challenges for clinical transformation.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DC vaccine; Delivery strategy; Immunogenic cell death; Liposome; Microorganism; Neoantigen; Polymer; Precise medicine; Whole cancer cell vaccine

Mesh:

Substances:

Year:  2021        PMID: 34403752     DOI: 10.1016/j.addr.2021.113927

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  2 in total

Review 1.  Nanobiotherapeutic strategies to target immune microenvironment of triple-negative breast cancer.

Authors:  Qing Chang; Liang Chang; Mo Li; Liwen Fan; Shunchao Bao; Xinyu Wang; Linlin Liu
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

2.  Inducing immunogenic cell death in immuno-oncological therapies.

Authors:  Dongdong Ti; Xin Yan; Jianshu Wei; Zhiqiang Wu; Yao Wang; Weidong Han
Journal:  Chin J Cancer Res       Date:  2022-02-28       Impact factor: 5.087

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.